Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 9 de 9 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2.Tiene citas relacionadas Cita con resumen
Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med 2009;361:2113-22. [Ref.ID 87070]
3.Tiene citas relacionadas Cita con resumen
Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russsell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes. The SANDS randomized trial. JAMA 2008;299:1678-89. [Ref.ID 82594]
4.Tiene citas relacionadas Cita con resumen
McFadden EP, Stabile E, Regar E, Cheneau E, Ong ATL, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard A D, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21. [Ref.ID 71723]
5.
Park SJ, Shim WH, Ho DS, Raizner A E, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GS. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 2003;348:1537-45. [Ref.ID 65756]
6. Cita con resumen
Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid C L. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. JAMA 2001;286:2011-4. [Ref.ID 58897]
7.Tiene citas relacionadas Cita con resumen
Weissman NJ, Panza JA, Tighe JF, Gwynne JT. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. Ann Intern Med 2001;134:267-73. [Ref.ID 55719]
8.Tiene citas relacionadas
Weissman NJ, Gottdiener JS, Gwynne JT. Appetite-suppressant drugs and valvular heart disease. N Engl J Med 1999;340:479. [Ref.ID 42761]
9.Tiene citas relacionadas Cita con resumen
Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT, for the Sustained-Release Dexfenfluramine Study Group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998;339:725-32. [Ref.ID 40103]
Seleccionar todas
 
 1 a 9 de 9